American Shared Hospital Services (AMS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed performance with declining leasing revenue and gross margins, alongside a net loss. Despite some growth in direct patient care services, the inability to provide guidance, especially on profitability, and the lack of a stock buyback program are concerning. The Q&A section highlights management's reluctance to offer forward-looking statements, contributing to uncertainty. Although there is strategic expansion, the financial health indicators suggest a negative sentiment, likely resulting in a stock price decrease of 2% to 8% over the next two weeks.
Key Financial Performance
Total Revenue (Q4 2025) $7.7 million, a decrease of 14.8% year-over-year. This decline was primarily driven by the expiration of 3 Gamma Knife contracts and lower proton beam radiation therapy volumes.
Direct Patient Care Service Revenue (Q4 2025) $4.8 million, an increase of 2.6% year-over-year. This growth was driven primarily by increased procedures at the Puebla, Mexico facility and in Rhode Island.
Medical Equipment Leasing Revenue (Q4 2025) $2.9 million, a decline of 33.9% year-over-year. This was due to lower proton beam radiation therapy volumes and contract expirations.
Gross Margin (Q4 2025) $906,000 or 12%, compared to 35% in Q4 2024. This decline reflects lower treatment volumes and the continued shift in revenue mix towards direct patient services.
Net Loss Attributable to the Company (Q4 2025) $631,000 or $0.09 per diluted share, an improvement compared to a net loss of $1.6 million or $0.23 per diluted share in Q4 2024.
Adjusted EBITDA (Q4 2025) $868,000, compared to $3.8 million in Q4 2024.
Total Revenue (Full Year 2025) $28.1 million, compared to $28.3 million in 2024. Revenue remained relatively stable year-over-year.
Direct Patient Care Services Revenue (Full Year 2025) $15.5 million, an increase of 23.7% year-over-year. This growth reflects the company's ongoing strategic transition.
Leasing Revenue (Full Year 2025) $12.6 million, a decline year-over-year. This reflects the company's strategic transition.
LINAC Revenue (Full Year 2025) $11.5 million, an increase of 35.4% year-over-year.
Gamma Knife Revenue (Full Year 2025) $9.2 million, a decrease of 5.5% year-over-year.
Proton Beam Radiation Therapy Revenue (Full Year 2025) $7.4 million, a decline of 26% year-over-year.
LINAC Treatment Sessions (Full Year 2025) 28,147 sessions, more than doubled year-over-year. This reflects the first full year of operation for both Puebla and Rhode Island centers.
Gross Margin (Full Year 2025) $5.1 million or 18% of revenue, compared to $9.2 million in 2024. This decline reflects increased operating costs and lower leasing segment contributions.
Net Loss Attributable to the Company (Full Year 2025) $1.6 million or $0.23 per diluted share, compared to net income of $2.2 million in 2024. The prior year included a $3.8 million bargain purchase gain related to the Rhode Island acquisition.
Adjusted EBITDA (Full Year 2025) $5.5 million, compared to $8.9 million in 2024.
Cash (Year-End 2025) $3.7 million, compared to $11.3 million at the end of 2024. The decrease was primarily driven by $7.5 million in capital expenditures related to Rhode Island expansion and international investments.
Total Debt (Year-End 2025) $17.3 million, primarily associated with credit facilities.
Shareholders' Equity (Year-End 2025) $24 million or $3.66 per outstanding share, compared to $25.2 million or $3.92 per outstanding share at December 31, 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Direct Patient Care Model: Shifted towards a direct patient care model, now representing the majority of revenue, providing a stable and scalable platform for growth.
LINAC Treatments: Strong growth with treatment sessions more than doubling to 28,147 in 2025, driven by operations in Puebla, Mexico, and Rhode Island.
Gamma Knife Technology: Upgraded to state-of-the-art Esprit platform in Lima, Peru, improving treatment capabilities.
International Expansion: Relocated Lima, Peru center and upgraded technology; maintained leadership in Ecuador and Peru; exceeded expectations in Puebla, Mexico; and planned development of Guadalajara, Mexico center for 2026.
New Partnerships: Collaborated with Brown University Health in Rhode Island to rebuild physician base and improve treatment volumes.
Revenue Cycle Management: Enhanced infrastructure for better control over billing and collections, aiming to improve financial performance.
Cost Structure Alignment: Focused on aligning cost structure with operational scale to strengthen cash flow generation.
Partnership Strengthening: Extended 7-year lease with Orlando Health for proton beam radiation therapy system, exemplifying long-term collaboration.
Development Pipeline: Secured certificate of need approvals for new radiation therapy treatment center in Bristol and proton beam radiation therapy center in Johnston, Rhode Island, as major growth drivers.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Physician Turnover: Challenges in stabilizing and rebuilding the radiation oncology physician team, which impacted treatment volumes.
Reimbursement Dynamics: Issues with reimbursement dynamics that could affect financial performance.
Leasing Segment Headwinds: Decline in revenue from the Medical Equipment Leasing segment due to contract expirations and lower proton beam radiation therapy volumes.
Financial Covenants: Non-compliance with certain financial covenants due to lower profitability, higher operating costs, and reduced leasing contributions, raising concerns about the company's ability to continue as a going concern if unresolved.
Cash Flow and Debt: Significant decrease in cash reserves and high total debt, creating financial strain and dependency on lender negotiations for credit facility restructuring.
Gross Margin Decline: Reduction in gross margin due to lower treatment volumes and increased operating costs, impacting overall profitability.
International Expansion Risks: Capital expenditures for international investments and expansions, such as in Rhode Island and Mexico, have strained financial resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future treatment volume growth: The company expects improvements in treatment volumes in Rhode Island to continue into 2026, driven by stabilized physician staffing and operational enhancements.
International market expansion: Significant opportunities are anticipated in international markets, including the development of the Guadalajara, Mexico center, expected to begin operations in 2026. Additionally, new radiation therapy treatment centers in Bristol and Johnston, Rhode Island, are planned as long-term growth drivers.
Operational and financial improvements: The company is focused on increasing treatment volumes, driving operational efficiencies, improving margins, and aligning cost structures with operational scale to enhance financial flexibility over time.
Capital structure and lender engagement: Active discussions with lending partners are ongoing to amend and potentially restructure the credit facility, aiming to provide the flexibility needed to support the business plan and long-term growth.
Direct Patient Care Services growth: The Direct Patient Care Services segment is central to the long-term growth strategy, with significant expansion in 2025 and expectations for continued growth supported by operational improvements and new centers.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:As you deepen your footprint in Rhode Island, will you be able to help offset some of the noise caused by equipment upgrades by referring patients from one center to another?
A:Yes, leveraging the infrastructure over a bigger footprint is part of the strategy in Rhode Island, which includes economies of scale and regional development.
Q:What is the timeline for constructing the first new facility in Rhode Island, and how early before the center opens do you begin staffing initiatives?
A:The Bristol facility is expected to come online in late 2027, followed by the proton facility in 2028. Staffing typically begins several months in advance, utilizing existing teams to manage expenses during the initial ramp-up period.
Q:Will there be much downtime for professional staffing between hiring and the opening of the new facility?
A:No, there will not be much downtime as resources can be utilized at other sites during the interim period.
Q:Why are revenue surprises occurring due to expired contracts, and were these contracts disclosed in previous calls?
A:The expired contracts were disclosed in previous calls. These were cases where health systems decided to update equipment themselves rather than using the company for financing. Negative variances occur when comparing periods due to these expirations.
Q:Do you anticipate being profitable for 2026 overall?
A:The management declined to speculate on profitability for 2026, stating they do not provide forward-looking statements.
Q:Is the company constrained from buying back stock due to a credit agreement, or is it a decision not to pursue stock buybacks?
A:The company has not been interested in a stock buyback program, and under the current lender situation, this stance is unlikely to change.
Q:Would the company consider having directors take compensation in stock instead of cash to align their interests with investors?
A:The suggestion was noted, and management stated they would take it under consideration.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about profitability for 2026, citing a policy of not providing forward-looking statements.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bristol proton
Brown University
CharterCARE Health
Ecuador Peru
Esprit platform
Health Care
Health Rhode
Health lease
Health term
Island physician
Island runway
Johnston project
LINAC treatment
Lima Peru
Mexico center
Mr QA
Orlando Health
Scott
Services patient
University Health
access cancer
access radiation
action issue
addition focus
challenge
collaboration
driver
effort
foundation
improvement
infrastructure
investment
lending partner
partnership health
relationship
step
structure
AMS Transcript
American Shared Hospital Services (AMS) Q4 2025 Earnings Call Transcript
Unknown3-31
The earnings call reveals a mixed performance with declining leasing revenue and gross margins, alongside a net loss. Despite some growth in direct patient care services, the inability to provide guidance, especially on profitability, and the lack of a stock buyback program are concerning. The Q&A section highlights management's reluctance to offer forward-looking statements, contributing to uncertainty. Although there is strategic expansion, the financial health indicators suggest a negative sentiment, likely resulting in a stock price decrease of 2% to 8% over the next two weeks.
American Shared Hospital Services (AMS) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture with both positive and negative aspects. While there is growth in certain areas like the Puebla facility and Gamma Knife revenue, overall revenue and gross margins have declined year-over-year. The Q&A section reveals concerns about market valuation and management's vague responses. Despite some improvements in specific metrics, the lack of clear guidance and the company's thin trading volume suggest a neutral market reaction. Without a clear strategy to address these issues, the stock price is likely to remain stable in the short term.
American Shared Hospital Services (AMS) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals mixed signals: solid revenue growth and international expansion are offset by declining margins, increased expenses, and revenue drops in key areas. Although management shows optimism, the financials indicate challenges. Despite sequential improvements, year-over-year declines in key metrics and contract expirations raise concerns. The Q&A section highlights strategic staffing and partnerships, but these are not immediate catalysts. Without clear market cap data, a neutral rating is prudent, anticipating limited stock movement within -2% to 2% range due to offsetting positive and negative factors.
American Shared Hospital Services (AMEX:AMS) Q1 2025 Earnings Call Transcript
Unknown5-16
Despite strong revenue growth in direct patient services and international expansion, the earnings call revealed several negative factors: an EPS miss, declining treatment volumes, and increased operational expenses leading to a significant drop in adjusted EBITDA. The Q&A highlighted concerns about regulatory changes and management's vague responses added uncertainty. The lack of shareholder return initiatives further dampens sentiment. Overall, these factors suggest a negative stock price reaction in the coming weeks.
AMS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
